Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial
Elizabeth Furrie,Sandra Macfarlane,Aileen Kennedy,John H. Cummings,Shaun V. Walsh,O'neil Da,George T. Macfarlane +6 more
Reads0
Chats0
TLDR
Short term synbiotic treatment of active UC resulted in improvement of the full clinical appearance of chronic inflammation in patients receiving this therapy.Abstract:
Background and aims: Ulcerative colitis (UC) is an acute and chronic inflammatory disease of the large bowel with unknown aetiology. The immune response against normal commensal microorganisms is believed to drive inflammatory processes associated with UC. Therefore, modulation of bacterial communities on the gut mucosa, through the use of probiotics and prebiotics, may be used to modify the disease state. Methods: A synbiotic was developed for use in UC patients combining a probiotic, Bifidobacterium longum , isolated from healthy rectal epithelium, and a prebiotic (Synergy 1), a preferential inulin-oligofructose growth substrate for the probiotic strain. Treatment was employed in a double blinded randomised controlled trial using 18 patients with active UC for a period of one month. Clinical status was scored and rectal biopsies were collected before and after treatment, and transcription levels of epithelium related immune markers were measured. Results: Sigmoidoscopy scores (scale 0–6) were reduced in the test group (start 4.5 (1.4), end 3.1 (2.5)) compared with placebo (start 2.6 (2.1), end 3.2 (2.2)) (p = 0.06). mRNA levels for human beta defensins 2, 3, and 4, which are strongly upregulated in active UC, were significantly reduced in the test group after treatment (p = 0.016, 0.038, and 0.008, respectively). Tumour necrosis factor α and interleukin 1α, which are inflammatory cytokines that drive inflammation and induce defensin expression, were also significantly reduced after treatment (p = 0.018 and 0.023, respectively). Biopsies in the test group had reduced inflammation and regeneration of epithelial tissue. Conclusions: Short term synbiotic treatment of active UC resulted in improvement of the full clinical appearance of chronic inflammation in patients receiving this therapy.read more
Citations
More filters
Journal ArticleDOI
Prebiotic effects: metabolic and health benefits.
Marcel Roberfroid,Glenn R. Gibson,Lesley Hoyles,Anne L. McCartney,Robert A. Rastall,Ian Rowland,Danielle Wolvers,Bernhard Watzl,Hania Szajewska,Bernd Stahl,Francisco Guarner,Frédérique Respondek,Kevin Whelan,Véronique Coxam,Marie-Jeanne Davicco,Laurent Léotoing,Yohann Wittrant,Nathalie M. Delzenne,Patrice D. Cani,Audrey M. Neyrinck,Agnes Meheust +20 more
TL;DR: The present document has been written by a group of both academic and industry experts and aims to validate and expand the original idea of the prebiotic concept, defined as the selective stimulation of growth and/or activity of one or a limited number of microbial genus(era)/species in the gut microbiota that confer(s) health benefits to the host.
Journal ArticleDOI
Dominant and diet-responsive groups of bacteria within the human colonic microbiota.
Alan W. Walker,Jennifer Ince,Sylvia H. Duncan,Lucy M. I. Webster,Grietje Holtrop,Xiaolei Ze,David Stanley Brown,Mark D. Stares,Paul Scott,Aurore Bergerat,Petra Louis,Freda M McIntosh,Alexandra M. Johnstone,Gerald E. Lobley,Julian Parkhill,Harry J. Flint +15 more
TL;DR: Time courses obtained by targeted qPCR revealed that ‘blooms’ in specific bacterial groups occurred rapidly after a dietary change, and these were rapidly reversed by the subsequent diet.
Journal ArticleDOI
Probiotic Mechanisms of Action
Miriam Bermudez-Brito,Julio Plaza-Díaz,Sergio Muñoz-Quezada,Carolina Gomez-Llorente,Angel Gil +4 more
TL;DR: Probiotics modes of action focusing on how gut microbes influence the host are explored, with a clear understanding of these mechanisms allowing for appropriate probiotic strain selection for specific applications and may uncover novel probiotic functions.
Journal ArticleDOI
The influence of diet on the gut microbiota.
TL;DR: The current 'omic era promises rapid progress towards understanding how diet can be used to modulate the composition and metabolism of the gut microbiota, allowing researchers to provide informed advice, that should improve long-term health status.
Journal ArticleDOI
Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics
TL;DR: Inulin-derived oligosaccharides and GOS are mildly laxative, but can result in flatulence and osmotic diarrhoea if taken in large amounts.
References
More filters
Book
Biostatistics: A Foundation for Analysis in the Health Sciences
TL;DR: In this article, the Chi-square distribution and the analysis of Frequencies Nonparametric and Distribution-Free Statistics Vital Statistics are presented. But they do not consider the correlation analysis.
Journal ArticleDOI
Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversity
Journal ArticleDOI
Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria.
Maria Rescigno,Matteo Urbano,Barbara Valzasina,Maura Francolini,Gianluca Rotta,Roberto Bonasio,Francesca Granucci,Jean Pierre Kraehenbuhl,Paola Ricciardi-Castagnoli +8 more
TL;DR: A new mechanism for bacterial uptake in the mucosa tissues that is mediated by dendritic cells (DCs) is reported, which open the tight junctions between epithelial cells, send dendrites outside the epithelium and directly sample bacteria.
Journal ArticleDOI
Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene.
TL;DR: The data provide evidence for a primary role of the immune system in the etiology of ulcerative colitis and strongly suggest that the disease results from an abnormal immune response to a normal antigenic stimulus.
Journal ArticleDOI
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
TL;DR: The results suggest that treatment with a non-pathogenic E. coli has an equivalent effect to mesalazine in maintaining remission of ulcerative colitis.